Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-401-4060
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.50 million
Profitability
Miscellaneous
Employees72
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions
What is Ra Pharmaceuticals' stock symbol?
Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."
How were Ra Pharmaceuticals' earnings last quarter?
Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.03. View Ra Pharmaceuticals' Earnings History.
When is Ra Pharmaceuticals' next earnings date?
What price target have analysts set for RARX?
11 brokers have issued twelve-month price targets for Ra Pharmaceuticals' stock. Their forecasts range from $25.00 to $55.00. On average, they expect Ra Pharmaceuticals' share price to reach $46.09 in the next year. This suggests that the stock has a possible downside of 0.4%. View Analyst Price Targets for Ra Pharmaceuticals.
What is the consensus analysts' recommendation for Ra Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ra Pharmaceuticals.
Has Ra Pharmaceuticals been receiving favorable news coverage?
News headlines about RARX stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Ra Pharmaceuticals.
Are investors shorting Ra Pharmaceuticals?
Ra Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,300,000 shares, an increase of 24.5% from the August 30th total of 2,650,000 shares. Based on an average daily trading volume, of 464,400 shares, the short-interest ratio is presently 7.1 days. Approximately 8.5% of the company's stock are sold short. View Ra Pharmaceuticals' Current Options Chain.
Who are some of Ra Pharmaceuticals' key competitors?
Some companies that are related to Ra Pharmaceuticals include GALAPAGOS NV/S (GLPG), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Beigene (BGNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP) and Reata Pharmaceuticals (RETA).
What other stocks do shareholders of Ra Pharmaceuticals own?
Who are Ra Pharmaceuticals' key executives?
Ra Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
- Mr. David C. Lubner, Exec. VP & CFO (Age 55)
- Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
- Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
- Dr. Simon Read, Chief Scientific Officer (Age 48)
When did Ra Pharmaceuticals IPO?
(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.
Who are Ra Pharmaceuticals' major shareholders?
Ra Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.52%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Ra Pharmaceuticals stock include Alonso Ricardo, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, Rajeev M Shah, Ramin Farzaneh-Far and Simon Read. View Institutional Ownership Trends for Ra Pharmaceuticals.
Which major investors are buying Ra Pharmaceuticals stock?
RARX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Meeder Asset Management Inc.. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.
How do I buy shares of Ra Pharmaceuticals?
Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ra Pharmaceuticals' stock price today?
One share of RARX stock can currently be purchased for approximately $46.26.
How big of a company is Ra Pharmaceuticals?
Ra Pharmaceuticals has a market capitalization of $2.17 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.View Additional Information About Ra Pharmaceuticals.
What is Ra Pharmaceuticals' official website?
How can I contact Ra Pharmaceuticals?
Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]
MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
